|Bid||17.660 x N/A|
|Ask||17.720 x N/A|
|Day's Range||17.120 - 18.220|
|52 Week Range||9.900 - 28.700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 23, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.70|
Subscribe to Yahoo Finance Plus to view Fair Value for 9966.HKLearn more
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026 (KN026-306) was officially accepted by Center for Drug Evaluation (CDE), and will initiate a pivotal clinical study of KN026 combined with chemotherapy in advanced gastric and gastroesophageal junction cancer (GC/GEJ) patients who progressed after first-line standard chem
Alphamab Oncology (stock code: 9966.HK), announced that the first phase III pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-01) has successfully completed enrollment of all patients. A first interim analysis is going to be performed in the first quarter of 2022. Based on the data, the process of a first BLA submission of KN046 for the treatment of squamous NSCLC will be discussed with authorities and might be submitted as early as 2022.
Alphamab Oncology (stock code: 9966.HK), announced the company's interim results for the six months ended on June 30, 2021, and highlighted recent progress and upcoming milestones.